


Survey: Impact of COVID-19 Pandemic on Rare Disease Patients in Canada

Question	
<p>1. At this time, to the best of your knowledge, what is the most likely impact of COVID-19 on (adequate) supply of your company's drugs to Canadian patients? If the answer varies by drug, please provide either specific drug information or respond in general across all drugs.</p>	<p>We have taken proactive measures to mitigate the risk of potential interruptions in supply, and we are continuing to actively monitor this dynamic and rapidly evolving situation worldwide.</p>
<p>2. If interruption or shortage in drug supply were anticipated or took place, where could Canadian patients find information about the situation and any plans for addressing or mitigating the impact? Is there a website, information line, or contact person?</p>	<p>We have done our due-diligence to mitigate shortage of drug supply. In the event we foreseen such impact, external stakeholders will be</p>
<p>3. This question addresses any clinical trials that your company has at this time that includes Canadian sites or Canadian patients in other countries. At this time, to the best of your knowledge, have you experienced or do you anticipate any interruptions, delays, or modifications in the conduct of these trials due to COVID-19? Please describe any modifications or other adjustments.</p>	<p>Maintaining the integrity of our clinical trials remains paramount. At this time, we are not anticipating delays of our clinical trials related to COVID-19.</p>
<p>4. To the best of your knowledge, are there any clinical trials that will not take place or will be delayed as a result of COVID-19? Please describe.</p>	<p>At this time, we are not anticipating such impact of our clinical trials related to COVID-19.</p>
<p>5. Where can patients find information about any increased risk of getting COVID-19 or increased impact of COVID-19 due to any medications provided by your company?</p>	<p>Patients can communicate with their prescribing physician and/or communicate with the patient support program (OneSource) for additional information.</p>
<p>6. To the best of your knowledge, are there any changes in patient support programs that are anticipated or planned, related to issues due to COVID-19? Please describe.</p>	<p>As patient care remains to be the top priority, the patient support program (OneSource) continues to follow the WHO guidelines related to COVID-19. Services provided by the patient support program are not impacted by COVID-19 and remain best in class.</p>

7.	How can patients or patient organizations find updated information about your company's policies, plans, or actions related to COVID-19? How will you communicate with patients or patient groups?	We are actively communicating with the patient groups around plans and actions related to COVID-19.
8.	Is there any other information that you wish to communicate share at this time?	